📰 Curated Industry Article
This is a summary of a full article from a trusted healthcare and insurance publication. Click “Read Full Article” below to read the complete story.
The FDA has approved Novo Nordisk’s Awiqli as the first once-weekly, long-acting basal insulin for children 10 years and older with Type 2 diabetes.
Awiqli (insulin icodec-abae) injection, 700 units/milliliter, was approved as an adjunct to diet and exercise to improve glycemic control, according to an Oct. 23 news release from Novo Nordisk. The treatment reduces basal insulin injection frequency from seven times per week to one.
The approval was supported by evidence from studies in adults with Type 2 diabetes and a single-dose pharmacokinetic study in pediatric patients ages 10 to 17. Efficacy and safety were also demonstrated in the ONWARDS clinical trial program.
Awiqli is available at more than 70,000 pharmacies nationwide.
The post FDA approves 1st once-weekly insulin for children appeared first on Becker’s Hospital Review | Healthcare News & Analysis.
💡 What This Means For You
[armfox_dynamic_insight]
ARMFOX HEALTHCARE
Stay Informed. Protect Your Future.
No pressure. No jargon. Just honest answers from advisors who genuinely care about your family’s protection.
📰 This article is sourced from a trusted healthcare and insurance industry publication. Armfox Healthcare shares this for informational purposes only. Always consult a licensed advisor for personalized guidance.